Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial
By
Anna Bawden
Summary
A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial for treating type 2 diabetes. The study involving 930 adults found the drug reduced blood-sugar levels and body weight by engaging multiple metabolic pathways, including increasing energy expenditure through glucagon receptor activation. Unlike existing medications like Ozempic, Wegovy, or Mounjaro, retatrutide targets three gut hormones simultaneously. Experts note the results are striking but emphasize further testing is needed.
Source
bskyTriple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trialtheguardian.comKey quotes
· 3 pulledThe triple hormone drug mimics three gut hormones that help control your appetite, blood sugar and metabolism: GLP-1, GIP and glucagon.
Unlike other diabetes medications such as Ozempic and Wegovy, which primarily target the GLP-1 pathway to suppress appetite, or Mounjaro, which contains GLP-1 plus GIP to control blood-sugar levels, retatrutide also engages the glucagon receptor, which helps increase energy expenditure.
Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests needed
You might also wanna read
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
Study: Most Patients Regain Weight and Lose Health Benefits After Stopping GLP-1 Drugs
A study on tirzepatide (a GLP-1 drug) found that after stopping the medication, 82% of participants regained at least 25% of the weight they
arstechnica.com·6mo ago
Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t
theguardian.com·5mo ago
ADA 2026 Scientific Sessions: New GLP-1 Drugs and Diabetes Research Highlights
In this JAMA Medical News podcast, Jennifer Abbasi interviews Dr. Rita Kalyani, the ADA's Chief Scientific and Medical Officer, about key hi
ja.ma·3d ago
Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism
This research article demonstrates that semaglutide, a GLP-1 receptor agonist, provides chondroprotective effects in osteoarthritis mouse mo
GLP-1 Therapy Reduces Migraine Frequency by More Than Half in Obesity Patients
A study from the University of Naples found that liraglutide, a GLP-1 receptor agonist typically used for diabetes and obesity, significantl
medlink.com·6mo agoComments
Sign in to join the conversation.
No comments yet. Be the first.